Tag : EXACERBATIONS

OBERON and TITANIA demonstrated that tozorakimab significantly reduced the annualized rate of moderate/severe exacerbations vs. placebo in patients with COPD and a history of exacerbations. The benefit was consistently observed across smoking status, airflow obstruction, and BEC subgroups, with a safety profile generally similar to placebo, apart from a higher incidence of injection-site reactions.

A real-world study showed higher clinical remission rates when fluticasone furoate/umeclidinium/vilanterol was initiated as initial maintenance therapy vs. step-up from iCS-containing regimens. Reductions in exacerbation rates and improvements in lung function further support timely triple-therapy initiation in eligible patients with uncontrolled asthma.

In the NOVELTY study, higher baseline blood eosinophils (EOS) significantly predicted increased exacerbation risks in asthma and chronic obstructive pulmonary disease (COPD). Conversely, FeNO showed highly heterogeneous associations, paradoxically linking to a lower overall risk in COPD but increased odds of oral corticosteroid-treated exacerbations in asthma and asthma + COPD.
